WASHINGTON—An experimental class of cholesterol-lowering drugs is emerging as the most promising new weapon against cardiovascular disease since the widely used medicines called statins first reached the market more than 25 years ago.. In a flurry of studies presented over the weekend at the annual meeting of the American College of Cardiology, the drugs, known as PCSK9 inhibitors, were shown to reduce LDL cholesterol levels by half to two-thirds across several different patient groups. Elevated LDL or bad cholesterol is a key...
  